NCT00022256View on ClinicalTrials.gov

Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2001

Primary Completion Date

April 30, 2003

Study Completion Date

April 30, 2003

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

motexafin gadolinium

RADIATION

radiation therapy

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00022256 - Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter